Alvimopan - CAS 156053-89-3
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
Alvimopan
Catalog Number:
156053-89-3
Synonyms:
2-[[(2S)-2-benzyl-3-[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethylpiperidin-1-yl]propanoyl]amino]acetic acid ADL 8-2698 ADL8-2698 alvimopan alvimopan anhydrous anhydrous alvimopan Entereg LY 246736 LY-246736 LY246736 trans-3,4-dimethyl-4-(3-hydroxyphenyl) pipe
CAS Number:
156053-89-3
Description:
Alvimopan is a novel, oral, peripherally acting antagonist of the mu opioid receptor, which can help gastrointestinal recovery after surgery. Phase III IC50: Mu-type opioid receptor= 1.7 nM
Molecular Weight:
424.53
Molecular Formula:
C25H32N2O4
Quantity:
Grams-Kilos
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CC1CN(CCC1(C)C2=CC(=CC=C2)O)CC(CC3=CC=CC=C3)C(=O)NCC(=O)O
InChI:
1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1
InChIKey:
UPNUIXSCZBYVBB-JVFUWBCBSA-N
Targets:
Opioid Receptor
Current Developer:
Adolor Corporation; Cubist Pharmaceuticals
Chemical Structure
CAS 156053-89-3 Alvimopan

Related Opioid Receptor Products


CAS 244218-51-7 JTC-801

JTC-801
(CAS: 244218-51-7)

JTC-801 is a selective opioid receptor-like1 (ORL1) receptor antagonist with IC50 of 94 nM, weakly inhibits receptors δ, κ, and μ. It is an opioid analgesic dru...

CAS 357-08-4 Naloxone hydrochloride

Naloxone hydrochloride
(CAS: 357-08-4)

Naloxone HCl is an opioid inverse agonist drug used to counter the effects of opiate overdose.

CAS 58-74-2 Papaverine

Papaverine
(CAS: 58-74-2)

Papaverine is an opiate alkaloid isolated from the plant Papaver somniferum. It is used primarily in the treatment of visceral spasm, vasospasm. It is also used...

CAS 34552-83-5 Loperamide HCl

Loperamide HCl
(CAS: 34552-83-5)

Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.

CAS 39133-31-8 Trimebutine

Trimebutine
(CAS: 39133-31-8)

Trimebutine is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

CAS 59263-76-2 Meptazinol Hydrochloride

Meptazinol Hydrochloride
(CAS: 59263-76-2)

Meptazinol is a unique centrally active opioid analgesic, which inhibits [3H]-dihydromorphine binding with IC50 of 58 nM.

Odelepran
(CAS: 676501-25-0)

Odelepran is a opioid receptor antagonist. It is used for the treatment of alcohol dependence. It was developed by Lilly and was in clinical phase 2 trial, but ...

Bevenopran
(CAS: 676500-67-7)

Bevenopran is a peripherally selective μ- and δ-opioid receptor antagonist. It is used for the treatment of chronic opioid-induced constipation. It was develope...

CAS 152657-84-6 Nalfurafine

Nalfurafine
(CAS: 152657-84-6)

Nalfurafine is a selective and centrally-penetrant κ-opioid receptor (KOR) agonist without significant activity on μ- and δ-opioid receptors. With antipruritic ...

CAS 361444-66-8 JDTic

JDTic
(CAS: 361444-66-8)

A 4-phenylpiperidine derivative, for the κ-opioid receptor.

CAS 152-02-3 Levallorphan

Levallorphan
(CAS: 152-02-3)

Levallorphan, an allylmorphinan derivative, has been found to be a μ-opioid receptor antagonist that could be an analgesic agent as an prescription drug.

CAS 58569-55-4 Met-Enkephalin

Met-Enkephalin
(CAS: 58569-55-4)

Met-Enkephalin is synthetic opioid peptides that has opioid effects of a relatively short duration.

TRV130 Racemate
(CAS: 1401028-25-8)

The racemate form of TRV130 which is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy.

Lexanopadol
(CAS: 1357348-09-4)

Lexanopadol is a potent Opioid mu receptor agonist originated by Grunenthal. Lexanopadol is suited for the management of moderate to severe chronic pain, includ...

CAS 850173-95-4 ADL5859 HCl

ADL5859 HCl
(CAS: 850173-95-4)

ADL5859 HCl is a δ-opioid receptor agonist with Ki of 0.8 nM, selectivity against opioid receptor κ, μ, and weak inhibitory activity at the hERG channel.

TRV130
(CAS: 1401028-24-7)

TRV130 is an oxaspiro compound that has been found to be a μ-opioid receptor G protein ligand and could be used in pain therapy. IC50: 8.1 (pEC50. G protein ass...

PZM-21
(CAS: 1997387-43-5)

PZM-21 is a potent Gi activator which has selectivity for μOR. It is an experimental opioid analgesic drug promisingly used for the treatment of pain. Study ind...

Enadoline hydrochloride
(CAS: 124439-07-2)

Enadolineis a potent selective Opioid kappa receptor agonists originated by Pfizer. However, clinical trials for the treatment of Arrhythmias, Neuroprotection a...

CAS 1108147-88-1 MCOPPB triHydrochloride

MCOPPB triHydrochloride
(CAS: 1108147-88-1)

The trihydrochloride salt form of MCOPPB, an effective full agonist of nociceptin receptor, could be a good antianxiety agent with few side-effects. pKi: 10.07.

LY2795050
(CAS: 1346133-08-1)

LY2795050, a κ-opioid Receptor antagonist, has been found to be effective in imaging KOR behaving as a PET tracer. IC50: 0.72 nM and 25.8 nM for κ-opioid Recept...

Reference Reading


1.Are we doing "better"? The discrepancy between perception and practice of enhanced recovery after cystectomy principles among urologic oncologists.
Baack Kukreja JE1, Messing EM2, Shah JB3. Urol Oncol. 2016 Mar;34(3):120.e17-21. doi: 10.1016/j.urolonc.2015.10.002. Epub 2015 Nov 14.
PURPOSE: The concept of enhanced recovery after surgery has been around since the 1990s when it was first introduced as a means to improve postoperative recovery of general surgical patients. In the field of urology, the uptake of enhanced recovery pathways has been slow for unclear reasons. Recently, interest in enhanced recovery after cystectomy (ERAC) has been increasing, but the current urologic oncology practice patterns remain unclear. In this study, we investigate modern perioperative patterns of care and rates of application of ERAC principles by cystectomy surgeons.
2.New Options in Constipation Management.
Davis M1,2,3, Gamier P4,5,6. Curr Oncol Rep. 2015 Dec;17(12):55. doi: 10.1007/s11912-015-0481-x.
Constipation is common in the general population and for those on opioids and/or who are suffering from advanced cancer. Self-management consists of dietary changes, exercise, and laxatives. However, responses to self-management efforts are often inadequate to relieve the subjective and objective experience of constipation. Multiple new anti-constipating medications have recently been tested in randomized trials and the following are available commercially: probiotics, prucalopride, lubiprostone, linaclotide, elobixibat, antidepressants, methylnaltrexone, alvimopan, and naloxegol. This review will discuss the evidence-based benefits of these medications and outline an approach to managing constipation.
3.Pharmacological management to prevent ileus in major abdominal surgery: a systematic review and meta-analysis.
Drake TM1,2, Ward AE3. J Gastrointest Surg. 2016 Apr 12. [Epub ahead of print]
BACKGROUND: Prolonged ileus is a common complication following gastrointestinal surgery, with an incidence of up to 40 %. Investigations examining pharmacological treatment of ileus have proved largely disappointing; however, recently, several compounds have been shown to have benefited when used as prophylaxis to prevent ileus.
4.Constipation: opioid antagonists in people prescribed opioids.
Ahmedzai SH1, Boland JW. BMJ Clin Evid. 2015 Sep 11;2015. pii: 2407.
INTRODUCTION: Constipation is a common adverse effect of opioids. As an example, constipation is reported in 52% of people with advanced malignancy, and this figure rises to 87% in people who are terminally ill and taking opioids. There is no reason to believe that people with chronic non-malignant disease who are prescribed opioids will be any less troubled by this adverse effect.